4.4 Article

Which parameters predict the beneficial effect of GnRHa treatment on height in girls with central precocious puberty?

期刊

CLINICAL ENDOCRINOLOGY
卷 94, 期 5, 页码 804-810

出版社

WILEY
DOI: 10.1111/cen.14420

关键词

body height; bone age measurement; central precocious puberty; child; gonadotropin‐ releasing hormone; idiopathic sexual precocity; leuprolide

向作者/读者索取更多资源

The study aimed to determine which girls with idiopathic CPP (iCPP) will benefit from GnRHa treatment in terms of height gain. The most important factor influencing height gain was the chronological age (CA) at treatment onset. Girls treated before 6.4 years of age showed significant height gain, while those treated after 8.3 years did not reach the target. Advanced bone age (BA), basal estradiol (E-2), and pubertal stage were significant factors affecting height gain in girls treated between 6.4 and 8.3 years, with all cases meeting certain criteria showing significant height gain.
Objective Data about GnRHa on adult height in girls with central precocious puberty (CPP) have shown variable results, ranging from improvement of growth prognosis to lack of any benefit. This study was designed to delineate the criteria to decide which girls with idiopathic CPP (iCPP) will have a height benefit from GnRHa treatment. Design Retrospective Patients 102 girls with iCPP who had reached final height (FH) were included. Measurements Auxological, hormonal and radiological findings at treatment onset, and FHs were extracted from records. Results Most important factor affecting height gain was chronological age (CA) at treatment onset. All the girls treated <= 6.4 years of age achieved a height gain of >= 1SDS, while none of the girls treated >= 8.3 years of age made the target. 75.6% of patients who started GnRHa between the ages of 6.4 and 8.3 years had a height gain of >= 1SDS. Most important factors affecting height gain in those treated 6.4-8.3 years were advanced bone age (BA), basal estradiol (E-2) and pubertal stage (r(2): 0.906; P < .001). All individuals with BA advancement of >= 2.6 years or E-2 of >= 32.6 pg/ml or pubertal stage of >= 3 had significant height gain, and none of the cases with BA advancement of BA (>= 2.6 years over CA) and pubertal findings (pubertal stage >= 3 or E-2 >= 32.6 pg/ml) are well-advanced.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据